Institutions / Deerfield Management Company, L.P. / Activity
Activity — Deerfield Management Company, L.P.
112 moves.
| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2026 as of | Exit | G4766E116 Common stock | $-121.74M | -3.4M -100.00% | 0 | high |
| Q1 2026 as of | New | Indivior Pharmaceuticals, Inc. Common stock | $94.42M | +3.1M | 3,097,790 1.41% of portfolio | high |
| Q1 2026 as of | New | Syndax Pharmaceuticals Inc Common stock | $88.30M | +3.8M | 3,779,900 1.32% of portfolio | high |
| Q1 2026 as of | New | Dianthus Therapeutics, Inc. Common stock | $85.58M | +1.0M | 1,019,813 1.28% of portfolio | high |
| Q1 2026 as of | New | Pfizer Inc Common stock | $85.36M | +3.0M | 3,040,000 1.27% of portfolio | high |
| Q1 2026 as of | Trim | Neurocrine Biosciences Inc Common stock | $-75.66M | -574K -48.49% | 610,000 1.20% of portfolio | high |
| Q1 2026 as of | New | 372303206 Common stock | $66.06M | +2.5M | 2,462,000 0.98% of portfolio | high |
| Q1 2026 as of | Add | Xenon Pharmaceuticals Inc. Common stock | $62.43M | +1.1M +198.09% | 1,615,696 1.40% of portfolio | high |
| Q1 2026 as of | Add | Inspire Medical Systems, Inc. Common stock | $61.76M | +1.2M +79.51% | 2,703,238 2.08% of portfolio | high |
| Q1 2026 as of | Trim | Revolution Medicines, Inc. Common stock | $-58.12M | -598K -20.65% | 2,297,000 3.33% of portfolio | high |
| Q1 2026 as of | New | BioMarin Pharmaceutical Inc Common stock | $48.10M | +852K | 851,556 0.72% of portfolio | medium |
| Q1 2026 as of | Exit | Phreesia, Inc. Common stock | $-33.82M | -2.0M -100.00% | 0 | medium |
| Q1 2026 as of | Add | LEGN Legend Biotech Corp ADR | $31.76M | +1.8M +29.60% | 7,687,638 2.07% of portfolio | medium |
| Q1 2026 as of | Exit | Ventas, Inc. Common stock | $-27.39M | -354K -100.00% | 0 | medium |
| Q1 2026 as of | Add | Tango Therapeutics, Inc. Common stock | $25.94M | +1.2M +42.65% | 4,146,813 1.29% of portfolio | medium |
| Q1 2026 as of | Trim | Catalyst Pharmaceuticals, Inc. Common stock | $-23.96M | -968K -19.70% | 3,943,600 1.46% of portfolio | medium |
| Q1 2026 as of | Exit | Spyre Therapeutics, Inc. Common stock | $-23.28M | -711K -100.00% | 0 | medium |
| Q1 2026 as of | Add | Larimar Therapeutics, Inc. Common stock | $22.50M | +5.0M +16.34% | 35,606,974 2.39% of portfolio | medium |
| Q1 2026 as of | New | Tyra Biosciences, Inc. Common stock | $21.03M | +549K | 549,000 0.31% of portfolio | medium |
| Q1 2026 as of | Trim | Ideaya Biosciences, Inc. Common stock | $-20.76M | -623K -28.94% | 1,530,008 0.76% of portfolio | medium |
| Q1 2026 as of | New | Bright Minds Biosciences Inc. Common stock | $20.65M | +283K | 283,000 0.31% of portfolio | medium |
| Q1 2026 as of | Add | Praxis Precision Medicines, Inc. Common stock | $19.33M | +60K +6.64% | 963,351 4.63% of portfolio | medium |
| Q1 2026 as of | Exit | Edgewise Therapeutics, Inc. Common stock | $-19.00M | -766K -100.00% | 0 | medium |
| Q1 2026 as of | Add | United Therapeutics Corp Common stock | $18.39M | +31K +7.28% | 457,000 4.04% of portfolio | medium |
| Q1 2026 as of | Trim | Centene Corp Common stock | $-17.38M | -531K -8.23% | 5,917,091 2.89% of portfolio | medium |
| Q1 2026 as of | Trim | Arrowhead Pharmaceuticals, Inc. Common stock | $-16.28M | -260K -14.17% | 1,573,297 1.47% of portfolio | medium |
| Q1 2026 as of | New | SGP SpyGlass Pharma, Inc. Common Stock | $14.25M | +550K | 550,000 0.21% of portfolio | medium |
| Q1 2026 as of | Trim | Vera Therapeutics, Inc. Common stock | $-13.58M | -338K -8.32% | 3,722,100 2.23% of portfolio | medium |
| Q1 2026 as of | Exit | CorMedix Inc. Common stock | $-12.89M | -1.1M -100.00% | 0 | medium |
| Q1 2026 as of | Add | BLTE Belite Bio, Inc ADR | $11.19M | +70K +30.02% | 304,013 0.72% of portfolio | medium |
| Q1 2026 as of | Exit | Medline Inc. Common stock | $-10.92M | -260K -100.00% | 0 | medium |
| Q1 2026 as of | Add | IRON Disc Medicine, Inc. Common Stock | $9.32M | +146K +28.53% | 657,000 0.63% of portfolio | medium |
| Q1 2026 as of | Exit | OMDA Omada Health, Inc. Common Stock | $-8.73M | -553K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | CALC CalciMedica, Inc. Common Stock | $-8.57M | -1.3M -100.00% | 0 | medium |
| Q1 2026 as of | Add | MNPR Monopar Therapeutics Inc. Common Stock | $8.39M | +153K +89.82% | 323,745 0.26% of portfolio | medium |
| Q1 2026 as of | Add | Biocryst Pharmaceuticals Inc Common stock | $6.64M | +697K +4.86% | 15,038,000 2.13% of portfolio | medium |
| Q1 2026 as of | Exit | Prestige Consumer Healthcare Inc Common stock | $-4.30M | -70K -100.00% | 0 | low |
| Q1 2026 as of | Exit | Veeva Systems Inc Common stock | $-3.95M | -18K -100.00% | 0 | low |
| Q1 2026 as of | Add | Beta Bionics, Inc. Common stock | $3.86M | +386K +41.11% | 1,324,000 0.20% of portfolio | low |
| Q1 2026 as of | Exit | RadNet, Inc. Common stock | $-3.56M | -50K -100.00% | 0 | low |
| Q1 2026 as of | Add | Foghorn Therapeutics Inc. Common stock | $3.56M | +745K +20.42% | 4,394,367 0.31% of portfolio | low |
| Q1 2026 as of | Exit | Labcorp Holdings Inc. Common stock | $-3.47M | -14K -100.00% | 0 | low |
| Q1 2026 as of | Exit | Enovis CORP Common stock | $-3.39M | -127K -100.00% | 0 | low |
| Q1 2026 as of | Exit | Alignment Healthcare, Inc. Common stock | $-3.25M | -164K -100.00% | 0 | low |
| Q1 2026 as of | Add | N62509109 Common stock | $3.20M | +100K +2.40% | 4,264,789 2.03% of portfolio | low |
| Q1 2026 as of | Exit | Quest Diagnostics Inc Common stock | $-3.19M | -18K -100.00% | 0 | low |
| Q1 2026 as of | Exit | TransMedics Group, Inc. Common stock | $-3.10M | -25K -100.00% | 0 | low |
| Q1 2026 as of | Exit | Insulet Corp Common stock | $-3.02M | -11K -100.00% | 0 | low |
| Q1 2026 as of | Exit | Biolife Solutions Inc Common stock | $-2.91M | -120K -100.00% | 0 | low |
| Q1 2026 as of | Exit | Chemed Corp Common stock | $-2.66M | -6K -100.00% | 0 | low |